125 related articles for article (PubMed ID: 32489121)
1. Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy.
Shi J; Li M; Yang R
Immunotherapy; 2020 Jun; 12(9):641-652. PubMed ID: 32489121
[No Abstract] [Full Text] [Related]
2. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
3. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma.
Wang C; Li M; Wei R; Wu J
J Bone Oncol; 2020 Dec; 25():100332. PubMed ID: 33145154
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients.
Yu W; Sun M; Wang W; Shen Z; Wang Y; Li H
Support Care Cancer; 2024 Jun; 32(7):415. PubMed ID: 38847977
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
10. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
11. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma in patients over 50 years of age: Multi-institutional retrospective analysis of 104 patients.
Nagano A; Matsumoto S; Kawai A; Okuma T; Hiraga H; Matsumoto Y; Nishida Y; Yonemoto T; Hosaka M; Takahashi M; Yoshikawa H; Kunisada T; Asanuma K; Naka N; Emori M; Kubo T; Kawashima H; Kawamoto T; Yokoyama R; Tsukushi S; Sato K; Okamoto T; Hiraoka K; Morioka H; Tanaka K; Takagi T; Iwamoto Y; Ozaki T
J Orthop Sci; 2020 Mar; 25(2):319-323. PubMed ID: 31155441
[TBL] [Abstract][Full Text] [Related]
14. Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers.
Bouaoud J; Beinse G; Epaillard N; Amor-Sehlil M; Bidault F; Brocheriou I; Hervé G; Spano JP; Janot F; Boudou-Rouquette P; Benassarou M; Schouman T; Goudot P; Malouf G; Goldwasser F; Bertolus C
Oral Oncol; 2019 Aug; 95():79-86. PubMed ID: 31345398
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
16. Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
Takada K; Kashiwagi S; Asano Y; Goto W; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2019 Jun; 19(1):615. PubMed ID: 31234828
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.
Zhou X; Wu J; Duan C; Liu Y
J Immunol Res; 2020; 2020():7890985. PubMed ID: 33062726
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
19. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
